MJA
MJA

Primary care management of non-specific low back pain: key messages from recent clinical guidelines

Matheus Almeida, Bruno Saragiotto, Bethan Richards and Chris G Maher
Med J Aust 2018; 208 (6): . || doi: 10.5694/mja17.01152
Published online: 2 April 2018

Abstract

Introduction: Research in the past decade supports some major changes to the primary care management of non-specific low back pain (LBP). The present article summarises recommendations from recently published United Kingdom, Danish, Belgian and United States guidelines to alert readers to the important changes in recommendations for management, and the recommendations from previous guidelines that remain unchanged.

Main recommendations: Use a clinical assessment to triage patients with LBP. Further diagnostic workup is only required for the small number of patients with suspected serious pathology. For many patients with non-specific LBP, simple first line care (advice, reassurance and self-management) and a review at 1–2 weeks is all that is required. If patients need second line care, non-pharmacological treatments (eg, physical and psychological therapies) should be tried before pharmacological therapies. If pharmacological therapies are used, they should be used at the lowest effective dose and for the shortest period of time possible. Exercise and/or cognitive behavioural therapy, with multidisciplinary treatment for more complex presentations, are recommended for patients with chronic LBP. Electrotherapy, traction, orthoses, bed rest, surgery, injections and denervation procedures are not recommended for patients with non-specific LBP.

Changes in management as a result of the guidelines: The major changes include:

  • emphasising simple first line care with early follow-up;
  • encouraging non-pharmacological treatments over pharmacological treatments; and
  • recommending against the use of surgery, injections and denervation procedures.

 

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Drowning deaths in Australia caused by hypoxic blackout, 2002–2015

Richard C Franklin, Amy E Peden and John H Pearn
Med J Aust 2018; 208 (6): . || doi: 10.5694/mja17.00728
Published online: 2 April 2018

Hypoxic blackout, also called apnoeic hypoxia or shallow water blackout,1 is a distinct and largely preventable cause of drowning.2 This fatal syndrome is often the consequence of voluntary pre-submersion hyperventilation, which downregulates CO2 brainstem chemoreceptors, with the result that consciousness may be lost (because of apnoeic hypoxia) before protective breakpoints (driven by CO2 and O2 chemoreceptors) are reached.3 Inspiration thus begins while the person is submerged and unconscious. Given the paucity of population-level analyses,4 in this study we examined hypoxic blackout-related fatal drownings in Australia to in order to inform development of prevention strategies.

Please login with your free MJA account to view this article in full


Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.


  • 1 James Cook University, Townsville, QLD
  • 2 Royal Life Saving Society – Australia, Sydney, NSW
  • 3 Lady Cilento Children's Hospital, Brisbane, QLD


Correspondence: richard.franklin@jcu.edu.au

Acknowledgements: 

This research was supported by Royal Life Saving Society – Australia as part of its core role in promoting safety in all forms of aquatic activity. Research at Royal Life Saving Society – Australia is supported by the Australian Government.

Competing interests:

No relevant disclosures.

  • 1. International Life Saving Federation. Shallow water blackout (Medical Position Statement MPS 16). May 2011. https://www.ilsf.org/file/3926/download?token=qDk320rV (viewed Jan 2018).
  • 2. Pearn JH, Franklin RC, Peden AE. Hypoxic blackout: diagnosis, risks, and prevention. Int J Aquat Res Educ 2015; 9: 342-347.
  • 3. Nattie E. CO2, brainstem chemoreceptors and breathing. Prog Neurobiol 1999; 59: 299-331.
  • 4. Boyd C, Levy A, McProud T, et al. Fatal and nonfatal drowning outcomes related to dangerous underwater breath-holding behaviour: New York State, 1988–2011. MMWR Morb Mortal Wkly Rep 2015; 64: 518-521.
  • 5. Lindholm P, Gennser M. Aggravated hypoxia during breath-holds after prolonged exercise. Eur J Appl Physiol 2005; 93: 701-707.
  • 6. Lippmann J, Pearn J. Snorkelling-related deaths in Australia, 1994–2006. Med J Aust 2012; 197: 230-232. <MJA full text>
Online responses are no longer available. Please refer to our instructions for authors page for more information.

Changing trends in the incidence of invasive melanoma in Victoria, 1985–2015

David J Curchin, Victoria R Harris, Christopher J McCormack and Saxon D Smith
Med J Aust 2018; 208 (6): . || doi: 10.5694/mja17.00725
Published online: 2 April 2018

Abstract

Objectives: To estimate the incidence of cutaneous malignant melanoma in Victoria; to examine trends in its incidence over the past 30 years. Secondary objectives were to examine the anatomic location and thickness of invasive melanoma tumours during the same period.

Design: Population-based, descriptive analysis of Victorian Cancer Registry data.

Participants: Victorian residents diagnosed with melanoma, 1985–2015.

Main outcome measures: Age-standardised incidence of invasive melanoma; estimated annual percentage changes in incidence.

Results: In 2015, the incidence of invasive melanoma in Victoria was 52.9 cases per 100 000 men and 39.2 cases per 100 000 women. Since the mid-1990s, the incidence for men increased annually by 0.9% (95% CI, 0.3–1.5%), but for women there was no significant change (estimated annual percentage change, –0.1%; 95% CI, –0.8% to 0.5%). The incidence of invasive melanoma has been declining in age groups under 55 years of age since 1996 (overall annual change, –1.7%; 95% CI, –2.5% to –0.9%), but is still increasing in those over 55 (overall annual change, 1.6%; 95% CI, 1.0–2.2%). The most frequent site of tumours in men was the trunk (40%), on women the upper (32%) and lower limbs (31%).

Conclusions: Melanoma remains a significant health problem, warranting continued prevention efforts. Awareness of differences in presentation by men and women and in different age groups would facilitate improved screening and risk identification.

Please login with your free MJA account to view this article in full


Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.


  • 1 Northern Clinical School, University of Sydney, Sydney, NSW
  • 2 Royal North Shore Hospital, Sydney, NSW
  • 3 Peter MacCallum Cancer Centre, Melbourne, VIC


Correspondence: dcur0946@uni.sydney.edu.au

Competing interests:

No relevant disclosures.

  • 1. Australian Institute of Health and Welfare. Cancer in Australia 2017 (AIHW Cat. No. CAN 100; Cancer Series No. 101). Canberra: AIHW, 2017. https://www.aihw.gov.au/reports/cancer/cancer-in-australia-2017 (viewed Feb 2017).
  • 2. Baade P, Meng X, Youlden D, et al. Time trends and latitudinal differences in melanoma thickness distribution in Australia, 1990–2006. Int J Cancer 2012; 130: 170-178.
  • 3. Cancer Institute NSW. Cancer in NSW 2017. May 2017. https://www.cancerinstitute.org.au/cancer-data-pages (viewed May 2017).
  • 4. Cancer Council Queensland. Queensland cancer statistics online (QCSOL). 2017. https://cancerqld.org.au/research/queensland-cancer-statistics/queensland-cancer-statistics-online-qcsol/ (viewed Apr 2017).
  • 5. Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control 2001; 12: 69-82.
  • 6. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005; 41: 45-60.
  • 7. Montague M, Borland R, Sinclair C. Slip! Slop! Slap! and SunSmart, 1980–2000: skin cancer control and 20 years of population-based campaigning. Health Educ Behav 2001; 28: 290-305.
  • 8. Erdmann F, Lortet-Tieulent J, Schuz J, et al. International trends in the incidence of malignant melanoma 1953–2008 — are recent generations at higher or lower risk? Int J Cancer 2013; 132: 385-400.
  • 9. Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Invest Dermatol 2016; 136: 1161-1171.
  • 10. Boyle P, Parkin DM. Statistical methods for registries. In: Jensen OM, Parkin DM, MacLennan R, et al (editors), Cancer registration: principles and methods (IARC Scientific Publications No. 95). Lyon: International Agency for Research on Cancer, 1991; pp. 126-158. http://www.iarc.fr/en/publications/pdfs-online/epi/sp95/sp95-chap11.pdf (viewed May 2017).
  • 11. Australian Bureau of Statistics. 3101.0. Australian demographic statistics, June 2016 (table 52). Dec 2016. http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3101.0Jun%202016?OpenDocument (viewed May 2017).
  • 12. Baade PD, Youlden DR, Youl P, et al. Assessment of the effect of migration on melanoma incidence trends in Australia between 1982 and 2010 among people under 30. Acta Derm Venereol 2015; 95: 118-120.
  • 13. Kim H, Fay M, Feuer E, Midthune D. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19: 335-351 (correction: 2001; 20: 655).
  • 14. Youl PH, Youlden DR, Baade PD. Changes in the site distribution of common melanoma subtypes in Queensland, Australia over time: implications for public health campaigns. Br J Dermatol 2013; 168: 136-144.
  • 15. Holman DM, Freeman MB, Shoemaker ML. Trends in melanoma incidence among non-Hispanic whites in the United States, 2005 to 2014. JAMA Dermatol 2018; doi:10.1001/jamadermatol.2017.5541 [Epub ahead of print].
  • 16. Coory M, Baade P, Aitken J, et al. Trends for in situ and invasive melanoma in Queensland, Australia, 1982–2002. Cancer Causes Control 2006; 17: 21-27.
  • 17. Wei EX, Qureshi AA, Han J, et al. Trends in the diagnosis and clinical features of melanoma in situ (MIS) in US men and women: a prospective, observational study. J Am Acad Dermatol 2016; 75: 698-705.
  • 18. Toender A, Kjaer SK, Jensen A. Increased incidence of melanoma in situ in Denmark from 1997 to 2011: results from a nationwide population-based study. Melanoma Res 2014; 24: 488-495.
  • 19. Smithson SL, Pan Y, Mar V. Differing trends in thickness and survival between nodular and non-nodular primary cutaneous melanoma in Victoria, Australia. Med J Aust 2015; 203: 20. <MJA full text>
  • 20. Meani RE, Pan Y, McLean C, et al. The Victorian Melanoma Service: a 20-year review of an Australian multidisciplinary cancer service. Australas J Dermatol 2016; 57: 235-237.
  • 21. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
  • 22. Payette MJ, Katz M, Grant-Kels JM. Melanoma prognostic factors found in the dermatopathology report. Clin Dermatol 2009; 27: 53-74.
  • 23. Whiteman DC, Stickley M, Watt P, et al. Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 2006; 249: 3172-3177.
  • 24. Anderson WF, Pfeiffer RM, Tucker MA, Rosenberg PS. Divergent cancer pathways for early-onset and late-onset cutaneous malignant melanoma. Cancer 2009; 115: 4176-4185.
  • 25. Mar V, Roberts H, Wolfe R, et al. Nodular melanoma: a distinct clinical entity and the largest contributor to melanoma deaths in Victoria, Australia. J Am Acad Dermatol 2013; 68: 568-575.
  • 26. Karahalios E, English D, Thursfield V, et al. Second primary cancers in Victoria [Internet]. Melbourne: Cancer Council Victoria, 2009. http://www.cancervic.org.au/downloads/cec/Second-Primary-Cancers.pdf (viewed May 2017).
  • 27. van der Leest RJ, Flohil SC, Arends LR, et al. Risk of subsequent cutaneous malignancy in patients with prior melanoma: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2015; 29: 1053-1062.
  • 28. Hirst NG, Gordon LG, Scuffham PA, Green AC. Lifetime cost-effectiveness of skin cancer prevention through promotion of daily sunscreen use. Value Health 2012; 15: 261-268.
  • 29. Doran CM, Ling R, Byrnes J, et al. Benefit cost analysis of three skin cancer public education mass-media campaigns implemented in New South Wales, Australia. PLoS One 2016; 11: e0147665.
  • 30. Watts CG, Cust AE, Menzies SW, et al. Cost-effectiveness of skin surveillance through a specialized clinic for patients at high risk of melanoma. J Clin Oncol 2017; 35: 63-71.
Online responses are no longer available. Please refer to our instructions for authors page for more information.

An update to the AIS–AMA position statement on concussion in sport

Lisa J Elkington, Silvia Manzanero and David C Hughes
Med J Aust 2018; 208 (6): . || doi: 10.5694/mja17.01180
Published online: 2 April 2018

The best approach is to take concussion seriously, treat each case carefully and be conservative with return to sport processes

The Australian Institute of Sport (AIS) and Australian Medical Association (AMA) position statement on concussion in sport and its dedicated online platform (https://www.concussioninsport.gov.au) were launched in May 2016.1 The aims were to conduct a comprehensive assessment of the evidence and present it in a format that would be accessible to all stakeholders; and to develop a set of guidelines for concussion management that would suit Australians who sustained a concussion in any sport and any level of participation. However, concussion research and guideline development progresses at a very fast pace, and it has become clear that the project needs to be regularly revised and updated as knowledge of concussion in sport continues to evolve. The gold standard for concussion in sport guidelines is the proceedings of the consensus meeting of the Concussion in Sport Group (CISG), which meets every 4 years to compile and examine the most current evidence. The most recent meeting of the CISG took place in Berlin in October 2016 and the outcomes were released as a consensus statement in April 2017,2 accompanied by a series of systematic reviews covering many aspects of concussion research and management.3-7 It was therefore necessary to update the AIS–AMA position statement to incorporate several aspects of concussion detection tools and management guidelines arising from the Berlin consensus. We also incorporated our own analysis of the evidence8 and discussed the position statement with representatives from several contact and collision sports. The main changes are summarised in Box 1. The updated version of the AIS–AMA position statement in concussion in sport was launched in November 2017 as one of the most current and informed tools currently available in Australia.


  • 1 Australian Institute of Sport, Canberra, ACT
  • 2 Research Institute for Sport and Exercise, University of Canberra, Canberra, ACT


Correspondence: david.hughes@ausport.gov.au

Competing interests:

No relevant disclosures.

  • 1. Elkington LJ, Hughes DC. Australian Institute of Sport and Australian Medical Association position statement on concussion in sport. Med J Aust 2017; 206: 46-50. <MJA full text>
  • 2. McCrory P, Meeuwisse W, Dvorak J, et al. Consensus statement on concussion in sport—the 5th international conference on concussion in sport held in Berlin, October 2016. Br J Sports Med 2017; 51: 838-847.
  • 3. Schneider KJ, Leddy JJ, Guskiewicz KM, et al. Rest and treatment/rehabilitation following sport-related concussion: a systematic review. Br J Sports Med 2017; 51: 930-934.
  • 4. Kamins J, Bigler E, Covassin T, et al. What is the physiological time to recovery after concussion? A systematic review. Br J Sports Med 2017; 51: 935-940.
  • 5. Davis GA, Purcell LK. The evaluation and management of acute concussion differs in young children. Br J Sports Med 2014; 48: 98-101.
  • 6. Feddermann-Demont N, Echemendia RJ, Schneider KJ, et al. What domains of clinical function should be assessed after sport-related concussion? A systematic review. Br J Sports Med 2017; 51: 903-918.
  • 7. Echemendia RJ, Broglio SP, Davis GA, et al. What tests and measures should be added to the SCAT3 and related tests to improve their reliability, sensitivity and/or specificity in sideline concussion diagnosis? A systematic review. Br J Sports Med 2017; 51: 895-901.
  • 8. Manzanero S, Elkington LJ, Praet SF, et al. Post-concussion recovery in children and adolescents: A narrative review. J Concussion 2017; 1: 1-8.
  • 9. Echemendia RJ, Meeuwisse W, McCrory P, et al. The Concussion Recognition Tool 5th Edition (CRT5): Background and rationale. Br J Sports Med 2017; 51: 870-871.
  • 10. Echemendia RJ, Meeuwisse W, McCrory P, et al. The Concussion Recognition Tool 5th Edition (CRT5). Br J Sports Med 2017; 51: 872.
  • 11. Echemendia RJ, Meeuwisse W, McCrory P, et al. The Sport Concussion Assessment Tool 5th Edition (SCAT5). Br J Sports Med 2017; 51: 851-858.
  • 12. Davis GA, Purcell L, Schneider KJ, et al. The Child Sport Concussion Assessment Tool 5th Edition (Child SCAT5): background and rationale. Br J Sports Med 2017; 51: 859-861.
  • 13. Davis GA, Purcell L, Schneider KJ, et al. The Child Sport Concussion Assessment Tool 5th Edition (Child SCAT5). Br J Sports Med 2017; 51: 862-869.
  • 14. Davis GA, Anderson V, Babl FE, et al. What is the difference in concussion management in children as compared with adults? A systematic review. Br J Sports Med 2017; 51: 949-957.
  • 15. McLeod TC, Lewis JH, Whelihan K, Bacon CE. Rest and return to activity after sport-related concussion: a systematic review of the literature. J Athl Train 2017; 52: 262-287.
  • 16. Mez J, Daneshvar DH, Kiernan PT, et al. Clinicopathological evaluation of chronic traumatic encephalopathy in players of American football. JAMA 2017; 318: 360-370.
  • 17. McKee AC, Cantu RC, Nowinski CJ, et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol 2009; 68: 709-735.
Online responses are no longer available. Please refer to our instructions for authors page for more information.

Exercise: an essential evidence-based medicine

Anita Green, Craig Engstrom and Peter Friis
Med J Aust 2018; 208 (6): . || doi: 10.5694/mja18.00033
Published online: 2 April 2018

Despite all the evidence, doctors do not regularly prescribe physical activity and exercise

The Gold Coast 2018 Commonwealth Games are a celebration of sporting excellence. Over 4000 elite athletes from 70 countries will compete in 18 sports and seven para-sports. The extraordinary performances of these athletes will be the culmination of long term dedicated training programs. Many of the next generation of elite Australian sportsmen and women will be inspired by these athletes and para-athletes and will passionately commit to specialised training and exercise regimes to pursue their sporting dreams. Sadly, there is no evidence, at a population level, that spectators enjoying the performances of highly trained athletes will increase their own physical activity and exercise patterns long term.1


  • University of Queensland, Brisbane, QLD



Competing interests:

Anita Green is Chief Medical Officer of the Gold Coast 2018 Commonwealth Games.

  • 1. Bauman A, Murphy NM, Matsudo V. Is a population-level physical activity legacy of the London 2012 Olympics likely? J Phys Act Health 2013; 10: 1-3.
  • 2. Lee IM, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 2012; 380: 219-229.
  • 3. Pedersen BK, Saltin B. Exercise as medicine - evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand J Med Sci Sports 2015; 25: 1-72.
  • 4. Royal Australian College of General Practitioners. Handbook of non-drug interventions (HANDI). https://www.racgp.org.au/handi (viewed Feb 2018).
  • 5. Royal Australian College of General Practitioners. Smoking, nutrition, alcohol, physical activity (SNAP): a population health guide to behavioural risk factors in general practice. 2nd ed. Melbourne: RACGP, 2015. https://www.racgp.org.au/your-practice/guidelines/snap/ (viewed Feb 2018).
  • 6. Short CE, Hayman M, Rebar AL, et al. Physical activity recommendations from general practitioners in Australia. Results from a national survey. Aust NZ J Public Health 2016; 40: 83-90.
  • 7. Fie S, Norman I, While A. The relationship between physicians’ and nurses’ personal physical activity habits and their health-promotion practice: a systematic review. Health Educ J 2011; 72: 102-119.
  • 8. Lobelo F, de Quevedo I. The evidence in support of physicians and health care providers as physical activity role models. Am J Lifestyle Med 2014: 10: 36-52.
  • 9. Gnanendran A, Pyne D, Fallon K, et al. Attitudes of medical students, clinicians and sports scientists towards exercise counselling. J Sports Sci Med 2011; 10: 426-443.
  • 10. Holtz K, Kokotilo K, Fitzgerald B, et al. Exercise behaviour and attitudes among fourth-year medical students at the University of British Columbia. Can Fam Physician 2013; 59: 26-32.
  • 11. Stanford F, Durkin M, Blair S, et al. Determining levels of physical activity in attending physicians, resident and fellow physicians and medical students in the USA. Br J Sports Med 2012; 46: 360-364.
  • 12. Weight CJ, Sellon JL, Lessard-Anderson CR, et al. Physical activity, quality of life, and burnout among physician trainees: the effect of a team-based, incentivized exercise program. Mayo Clin Proc 2013; 88: 1435-1442.
  • 13. Cooke P, Tully M, Cupples M, et al. A randomised control trial of experiential learning to promote physical activity. Educ Primary Care 2013; 24: 427-435.
  • 14. Dunlop M, Murray A. Major limitations in knowledge of physical activity guidelines among UK medical students revealed: implications for the undergraduate medical curriculum. Br J Sports Med 2013; 47: 718-720.
  • 15. Campbell D. Doctors ‘know too little about nutrition and exercise’. The Guardian 2016; 20 Oct. https://www.theguardian.com/society/2016/oct/19/doctors-know-too-little-about-effects-of-nutrition-and-exercise (viewed Dec 2017).
  • 16. Dacey M, Kennedy M, Polak R, et al. Physical activity counselling in medical school education: a systematic review. Med Educ Online 2014; 19: 24325.
  • 17. Thornton J, Fremont P, Khan K, et al. Physical activity prescription: a critical opportunity to address a modifiable risk factor for the prevention and management of chronic disease: a position statement by the Canadian Academy of Sport and Exercise Medicine. Br J Sports Med 2016; 50: 1109-1114.
Online responses are no longer available. Please refer to our instructions for authors page for more information.

Traumatic cricket-related fatalities in Australia: a historical review of media reports

Peter Brukner, Thomas J Gara and Lauren V Fortington
Med J Aust 2018; 208 (6): . || doi: 10.5694/mja17.00908
Published online: 26 March 2018

Abstract

Objective: To undertake a historical review of direct trauma-related deaths in Australian cricket, both organised and informal.

Design, setting and participants: We conducted an extensive search of digitised print media (three databases) and traditional scientific literature (two databases) for on-field cricket incidents in Australia that resulted in deaths during the period 1858–2016.

Main outcomes and measures: Numbers of cricket-related deaths by decade; type of cricket match (organised match or training, or informal play); site of fatal injury (eg, head, chest); activity at the time of the incident (eg, batting, fielding, watching).

Results: 174 relevant deaths were identified. The number peaked in the 1930s (33 fatalities), with five deaths in the past 30 years. There were 83 deaths in organised settings, and 91 deaths in informal play (at school, 31; backyard, street or beach cricket, 60). Of the 72 deaths in organised settings for which the activity of the deceased was reported, 45 were batsmen, 11 were fielders, six were wicketkeepers, one a bowler, and three were umpires. Of the 45 batsmen, 26 died of injuries resulting from a blow by a ball to the head, 13 of blows to the chest, three of peritonitis, at least two of vertebral artery dissection, and one of tetanus. None of the five cricket-related deaths over the past 30 years were caused by head injuries.

Conclusions: There appears to have been a substantial decline in the number of cricket-related deaths in recent years, probably linked with the widespread use of helmets by batsmen and close-in fielders.

Please login with your free MJA account to view this article in full


Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.


  • 1 La Trobe Sport and Exercise Medicine Research Centre (LASEM), La Trobe University, Melbourne, VIC
  • 2 South Australian Museum, Adelaide, SA
  • 3 Australian Centre for Research into Injury in Sport and its Prevention (ACRISP), Federation University Australia, Ballarat, VIC


Correspondence: peterbrukner@gmail.com

Acknowledgements: 

We acknowledge the assistance of John Orchard with this study, and financial support from Cricket Australia. The Australian Centre for Research into Injury in Sport and its Prevention is one of the Research Centres for the Prevention of Injury and Protection of Athlete Health supported by the International Olympic Committee (IOC).

Competing interests:

Peter Brukner was employed as the Cricket Australia team doctor during 2012–2017. Thomas Gara received funding for this study from Cricket Australia.

  • 1. Bull A. Cricket has had too many “freak” deaths: players need better protection. The Guardian (Australian edition) 9 Dec 2014. https://www.theguardian.com/sport/2014/dec/09/cricket-freak-deaths-players-need-protection (viewed Dec 2017).
  • 2. Tripathi M, Shukla DP, Bhat DI, et al. Craniofacial injuries in professional cricket: no more a red herring. Neurosurg Focus 2016; 40: E11.
  • 3. Joseph C, Finch CF. The incidence of injury in Australian community level cricket players: a national overview of insurance claims from 2004–2013 (abstract). 5th World Congress of Science and Medicine in Cricket, 23-27 March 2015, Sydney; p. 40. http://slideslip.com/doc/79736/abstracts (viewed Dec 2017).
  • 4. van Mechelen W, Hlobil H, Kemper HC. Incidence, severity, aetiology and prevention of sports injuries. A review of concepts. Sports Med 1992; 14: 82-99.
  • 5. Svinth JR. Death under the spotlight: the Manuel Velasquez collection. Journal of Combative Sport [online]. Oct 2011. http://ejmas.com/jcs/velazquez/ (viewed Dec 2017).
  • 6. Gorman RM, Weeks D. Death at the ballpark. A comprehensive study of game-related fatalities of players, other personnel and spectators in amateur and professional baseball, 1862-2007. Jefferson (NC): McFarland & Co., 2009.
  • 7. Fortington LV, Bekker S, Finch CF. Online news media reporting of football-related fatalities in Australia: a matter of life and death. J Sci Med Sport 2017; doi:10.1016/j.jsams.2017.06.015 [Epub ahead of print].
  • 8. Kreisfeld R, Harrison JE, Pointer S. Australian sports injury hospitalisations 2011–12 (AIHW Cat. No. INJCAT 168; Injury Research and Statistics Series No. 92). Canberra: Australian Institute of Health and Welfare, 2014.
  • 9. Shaw L, Finch CF. Injuries to junior club cricketers: the impact of helmet regulations. Br J Sports Med 2008; 42: 437-440.
  • 10. Baird LC, Newman CB, Volk H, et al. Mortality resulting from head injury in professional boxing: case report. Neurosurgery 2010; 67: E519-E520.
  • 11. Boden BP, Breit I, Beachler JA, et al. Fatalities in high school and college football players. Am J Sports Med 2013; 41: 1108-1116.
  • 12. Neélaton A. Éléments de pathologie chirurgicale. 2nd edition, volume 4. Paris: Librairie Germer Ballière et Cie, 1876.
  • 13. Maron BJ, Estes NAM. Commotio cordis. N Engl J Med 2010; 362: 917-927.
  • 14. Doerer JJ, Haas TS, Estes NAMI, et al. Evaluation of chest barriers for protection against sudden death due to commotio cordis. Am J Cardiol 2007; 99: 857-859.
  • 15. Drewniak EI, Spenciner DB, Crisco JJ. Mechanical properties of chest protectors and the likelihood of ventricular fibrillation due to commotio cordis. J Appl Biomech 2007; 23: 282-288.
  • 16. Janda DH, Viano DC, Andrzejak DV, et al. An analysis of preventive methods for baseball-induced chest impact injuries. Clin J Sport Med 1992; 2: 172-179.
  • 17. Link MS, Bir C, Dau N, et al. Protecting our children from the consequences of chest blows on the playing field: a time for science over marketing. Pediatrics 2008; 122: 437-439.
  • 18. Viano DC, Andrzejak DV, Polley TZ, et al. Mechanism of fatal chest injury by baseball impact: development of an experimental model. Clin J Sport Med 1992; 2: 166-171.
  • 19. Maron BJ, Doerer JJ, Haas TS, et al. Commotio cordis and the epidemiology of sudden death in competitive lacrosse. Pediatrics 2009; 124: 966-971.
  • 20. Maron BJ, Gohman TE, Kyle SB, et al. Clinical profile and spectrum of commotio cordis. JAMA 2002; 287: 1142-1146.
  • 21. Maron BJ, Poliac L, Kaplan JA, et al. Blunt impact to the chest leading to sudden death from cardiac arrest during sports activities. N Engl J Med 1995; 333: 337-342.
  • 22. Kaplan JA, Karofsky PS, Volturo GA. Commotio cordis in two amateur ice hockey players despite the use of commercial chest protectors: case reports. J Trauma 1993; 34: 151-153.
  • 23. Opeskin K, Burke MP. Vertebral artery trauma. Am J Forensic Med Pathol 1998; 19: 206-217.
Online responses are no longer available. Please refer to our instructions for authors page for more information.

The management of epilepsy in children and adults

Piero Perucca, Ingrid E Scheffer and Michelle Kiley
Med J Aust 2018; 208 (5): . || doi: 10.5694/mja17.00951
Published online: 19 March 2018

Summary

 

  • The International League Against Epilepsy has recently published a new classification of epileptic seizures and epilepsies to reflect the major scientific advances in our understanding of the epilepsies since the last formal classification 28 years ago. The classification emphasises the importance of aetiology, which allows the optimisation of management.
  • Antiepileptic drugs (AEDs) are the main approach to epilepsy treatment and achieve seizure freedom in about two-thirds of patients.
  • More than 15 second generation AEDs have been introduced since the 1990s, expanding opportunities to tailor treatment for each patient. However, they have not substantially altered the overall seizure-free outcomes.
  • Epilepsy surgery is the most effective treatment for drug-resistant focal epilepsy and should be considered as soon as appropriate trials of two AEDs have failed. The success of epilepsy surgery is influenced by different factors, including epilepsy syndrome, presence and type of epileptogenic lesion, and duration of post-operative follow-up.
  • For patients who are not eligible for epilepsy surgery or for whom surgery has failed, trials of alternative AEDs or other non-pharmacological therapies, such as the ketogenic diet and neurostimulation, may improve seizure control.
  • Ongoing research into novel antiepileptic agents, improved techniques to optimise epilepsy surgery, and other non-pharmacological therapies fuel hope to reduce the proportion of individuals with uncontrolled seizures. With the plethora of gene discoveries in the epilepsies, “precision therapies” specifically targeting the molecular underpinnings are beginning to emerge and hold great promise for future therapeutic approaches.

 


  • 1 Royal Melbourne Hospital, Melbourne, VIC
  • 2 Monash University, Melbourne, VIC
  • 3 Epilepsy Research Centre, Austin Health, University of Melbourne, Melbourne, VIC
  • 4 Florey Institute of Neuroscience and Mental Health, Melbourne, VIC
  • 5 Royal Adelaide Hospital, Adelaide, SA


Correspondence: piero.perucca@mh.org.au

Acknowledgements: 

This work was supported by the Melbourne International Research Scholarship and the Melbourne International Fee Remission Scholarship from the University of Melbourne and the Warren Haynes Neuroscience Research Fellowship from the Royal Melbourne Hospital Neuroscience Foundation (P Perucca); and by a National Health and Medical Research Council (NHMRC) Program Grant (1091593, 2016–2020) and an NHMRC Senior Practitioner Fellowship (1104831, 2016–2020) (IE Scheffer).

Competing interests:

P Perucca has received honoraria from Eisai. IE Scheffer serves on the editorial boards of and ; may accrue future revenue on a pending patent on a therapeutic compound; has received speaker honoraria from Athena Diagnostics, UCB, GlaxoSmithKline, Eisai, and Transgenomic; has received scientific advisory board honoraria from Nutricia, UCB and GlaxoSmithKline; has received funding for travel from Athena Diagnostics, UCB and GlaxoSmithKline; and receives research support from the NHMRC, the Australian Research Council, the National Institutes of Health, the Health Research Council of New Zealand, March of Dimes, the Weizmann Institute of Science, Citizens United for Research in Epilepsy (CURE), the United States Department of Defense and the Perpetual Charitable Trustees.

  • 1. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005; 46: 470-472.
  • 2. Beghi E, Hesdorffer D. Prevalence of epilepsy — an unknown quantity. Epilepsia 2014; 55: 963-967.
  • 3. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2129-2143.
  • 4. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014; 55: 475-482.
  • 5. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58: 522-530.
  • 6. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58: 512-521.
  • 7. Raspall-Chaure M, Neville BG, Scott RC. The medical management of the epilepsies in children: conceptual and practical considerations. Lancet Neurol 2008; 7: 57-69.
  • 8. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol 2011; 10: 446-456.
  • 9. Perucca E. Introduction to the choice of antiepileptic drugs. In: Shorvon SD, Perucca E, Engel J, editors. The treatment of epilepsy, 4th ed. Oxford: Wiley-Blackwell, 2015; pp 365-375.
  • 10. Perucca P, Jacoby A, Marson AG, et al. Adverse antiepileptic drug effects in new-onset seizures: a case-control study. Neurology 2011; 76: 273-279.
  • 11. Brodie MJ, Barry SJ, Bamagous GA, et al. Patterns of treatment response in newly diagnosed epilepsy. Neurology 2012; 78: 1548-1554.
  • 12. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369: 1000-1015.
  • 13. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369: 1016-1026.
  • 14. Brodie MJ, Perucca E, Ryvlin P, et al; Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68: 402-408.
  • 15. Baulac M, Brodie MJ, Patten A, et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol 2012; 11: 579-588.
  • 16. Baulac M, Rosenow F, Toledo M, et al. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol 2017; 16: 43-54.
  • 17. Tomson T, Marson A, Boon P, et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia 2015; 56: 1006-1019.
  • 18. Patel SI, Pennell PB. Management of epilepsy during pregnancy: an update. Ther Adv Neurol Disord 2016; 9: 118-129.
  • 19. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51: 1069-1077.
  • 20. Ryvlin P, Cross JH, Rheims S. Epilepsy surgery in children and adults. Lancet Neurol 2014; 13: 1114-1126.
  • 21. Friedman D, Devinsky O. Cannabinoids in the treatment of epilepsy. N Engl J Med 2015; 373: 1048-1058.
  • 22. Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017; 376: 2011-2020.
  • 23. Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 2015; 56: 1246-1251.
  • 24. French J, Thiele E, Mazurkiewicz-Beldzinska M, et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4)(S21.001). Neurology 2017; 88: S21.001.
  • 25. Wirrell E, Devinsky O, Patel A, et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose ranging, multicenter, randomized, double blind, placebo controlled trial (GWPCARE3). Ann Neurol 2017; 82: S279.
  • 26. Therapeutic Goods Administration. Access to medicinal cannabis products [website]. Canberra: TGA; 2017. https://www.tga.gov.au/access-medicinal-cannabis-products (viewed Aug 2017).
  • 27. Wiebe S, Blume WT, Girvin JP, Eliasziw M; Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 2001; 345: 311-318.
  • 28. Choi H, Sell RL, Lenert L, et al. Epilepsy surgery for pharmacoresistant temporal lobe epilepsy: a decision analysis. JAMA 2008; 300: 2497-2505.
  • 29. Engel J, Wiebe S, French J, et al. Practice parameter: temporal lobe and localized neocortical resections for epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons. Neurology 2003; 60: 538-547.
  • 30. Englot DJ, Ouyang D, Garcia PA, et al. Epilepsy surgery trends in the United States, 1990–2008. Neurology 2012; 78: 1200-1206.
  • 31. Engel J, McDermott MP, Wiebe S, et al. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA 2012; 307: 922-930.
  • 32. Englot DJ, Chang EF, Auguste KI. Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response. J Neurosurg 2011; 115: 1248-1255.
  • 33. DeGiorgio CM, Krahl SE. Neurostimulation for drug-resistant epilepsy. Continuum (Minneap Minn) 2013; 19: 743-755.
  • 34. Fisher R, Salanova V, Witt T, et al. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia 2010; 51: 899-908.
  • 35. Morrell MJ; RNS System in Epilepsy Study Group. Responsive cortical stimulation for the treatment of medically intractable partial epilepsy. Neurology 2011; 77: 1295-1304.
  • 36. Winesett SP, Bessone SK, Kossoff EH. The ketogenic diet in pharmacoresistant childhood epilepsy. Expert Rev Neurother 2015; 15: 621-628.
  • 37. Neal EG, Chaffe H, Schwartz RH, et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol 2008; 7: 500-506.
  • 38. Klein P, Tyrlikova I, Mathews GC. Dietary treatment in adults with refractory epilepsy: a review. Neurology 2014; 83: 1978-1985.
  • 39. Franco V, Perucca E. The pharmacogenomics of epilepsy. Expert Rev Neurother 2015; 15: 1161-1170.
  • 40. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature 2004; 428: 486.
  • 41. Amstutz U, Shear NH, Rieder MJ, et al. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia 2014; 55: 496-506.
  • 42. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364: 1134-1143.
  • 43. Chung WH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA 2014; 312: 525-534.
  • 44. Speed D, Hoggart C, Petrovski S, et al. A genome-wide association study and biological pathway analysis of epilepsy prognosis in a prospective cohort of newly treated epilepsy. Hum Mol Genet 2014; 23: 247-258.
  • 45. EpiPM Consortium. A roadmap for precision medicine in the epilepsies. Lancet Neurol 2015; 14: 1219-1228.
  • 46. Perucca P, Scheffer IE, Harvey AS, et al. Real-world utility of whole exome sequencing with targeted gene analysis for focal epilepsy. Epilepsy Res 2017; 131: 1-8.
  • 47. Engelsen BA, Tzoulis C, Karlsen B, et al. POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection. Brain 2008; 131: 818-828.
  • 48. Devinsky O, Hesdorffer DC, Thurman DJ, et al. Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention. Lancet Neurol 2016; 15: 1075-1088.
  • 49. Nashef L. Sudden unexpected death in epilepsy: terminology and definitions. Epilepsia 1997; 38: S6-S8.
  • 50. Harden C, Tomson T, Gloss D, et al. Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2017; 88: 1674-1680.
Online responses are no longer available. Please refer to our instructions for authors page for more information.

Obstructive airway disease in 46–65-year-old people in Busselton, Western Australia, 1966–2015

Arthur (Bill) Musk, Michael Hunter, Jennie Hui, Matthew W Knuiman, Mark Divitini, John P Beilby and Alan James
Med J Aust 2018; 208 (5): . || doi: 10.5694/mja17.00867
Published online: 19 March 2018

Abstract

Objective: To document the changing levels of tobacco smoking, respiratory symptoms, doctor-diagnosed asthma, and lung function in Busselton adults aged 46–65 years over the past 50 years.

Design, setting, participants: Repeated cross-sectional population surveys (1966 to 2010–2015) of adults registered to vote in the Busselton shire, Western Australia, including a modified version of the British Medical Research Council questionnaire on respiratory symptoms.

Main outcome measures: History of doctor-diagnosed asthma and chronic obstructive pulmonary disease (COPD), tobacco smoking history, respiratory medications used, spirometry parameters (forced expiratory volume in one second [FEV1], forced vital capacity [FVC]).

Results: The prevalence of tobacco smoking among men declined from 53% in 1966 to 12% in 2010–2015, and from 26% to 9% among women. The prevalence of ever-smoking (ie, smokers and ex-smokers) decreased from 80% to 57% for men but increased from 33% to 50% for women. The prevalence of doctor-diagnosed asthma increased, as did the use of long-acting bronchodilator aerosol medications by people with asthma and COPD. There have been no consistent changes in the prevalence of specific respiratory symptoms, but measures of lung function have significantly improved.

Conclusions: Smoking rates declined as a result of changes in pricing, prohibitions on smoking and the feedback of survey results to Busselton participants. Significant improvements in lung function were measured, and it can be anticipated that the prevalence of other smoking-related diseases will also decline.

Please login with your free MJA account to view this article in full


Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.


  • 1 Sir Charles Gairdner Hospital, Perth, WA
  • 2 University of Western Australia, Perth, WA
  • 3 Busselton Health Study Centre, Busselton Population Medical Research Institute, Busselton, WA
  • 4 Busselton Population Medical Research Institute, Perth, WA
  • 5 PathWest, Queen Elizabeth II Medical Centre, Perth, WA


Correspondence: jennie.hui@uwa.edu.au

Acknowledgements: 

We acknowledge the participation and support of the Busselton community. This investigation was funded by the National Health and Medical Research Council (grant 353532), Healthway WA, the Department of Health (Western Australia), and the Western Australian Office of Science.

Competing interests:

No relevant disclosures.

  • 1. Peat JK, Woolcock AJ, Leeder SR, et al Asthma and bronchitis in Sydney schoolchildren. II. The effect of social factors and smoking on prevalence. Am J Epidemiol 1980; 111: 728-735.
  • 2. Peat JK, Keena V, Harakeh Z, et al. Parental smoking and respiratory tract infections in children. Paediatr Respir Rev 2001; 2: 207-213.
  • 3. James AL, Palmer LJ, Kicic E, et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med 2005; 171: 109-114.
  • 4. Melén E, Granell R, Kogevinas M, et al. Genome-wide association study of body mass index in 23000 individuals with and without asthma. Clin Exp Allergy 2013; 43: 463-474.
  • 5. Cotes JE, Chinn DJ, Miller MR. Respiratory surveys. In: Lung function: physiology measurement and application in medicine. 6th edition. Oxford: Blackwell Publishing, 2006; pp 82-96.
  • 6. Renzetti AD. Standardization of spirometry. Am Rev Respir Dis 1979; 119: 831-838.
  • 7. American Thoracic Society. Standardization of spirometry: 1987 update. Am Rev Respir Dis 1987; 136: 1285-1298.
  • 8. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-1136.
  • 9. James AL, Knuiman MW, Divitini ML, et al. Associations between white blood cell count, lung function, respiratory illness and mortality: the Busselton Health Study. Eur Respir J 1999; 13: 1115-1119.
  • 10. Jamrozik E, Knuiman MW, James A, et al. Risk factors for adult-onset asthma: a 14-year longitudinal study. Respirology 2009; 14: 814-821.
  • 11. James AL, Knuiman MW, Divitini ML, et al. Changes in the prevalence of asthma in adults since 1966: the Busselton health study. Eur Respir J 2010; 35: 273-278.
  • 12. Gregory AT, Armstrong RM, Grassi TD, et al. On our selection: Australian longitudinal research studies. Med J Aust 2008; 189: 650-657. <MJA full text>
  • 13. Jamrozik E, Musk AW. Respiratory health issues in the Asia-Pacific region: an overview. Respirology 2011; 16: 3-12.
  • 14. Knuiman MW, Clarkson JP, Bulsara M, Bartholomew HC. Evaluating the impact of repeated community-wide health surveys on cardiovascular morbidity and mortality in the Busselton population. Aust N Z J Pub Health 2004; 28: 267-272.
Online responses are no longer available. Please refer to our instructions for authors page for more information.

Bedside cognitive assessment

Lorenzo Norris and Elizabeth L Cobbs
Med J Aust 2018; 208 (5): . || doi: 10.5694/mja17.00660
Published online: 19 March 2018

Screening for cognitive impairment may lead to diagnostic and treatment plans that improve patients’ safety

Mild memory changes and reduced speed of processing information are normal cognitive changes in older adults, but between 35% and 50% of adults over the age of 85 years have moderate to severe cognitive impairment. Cognitive impairment includes a range of conditions, such as mild cognitive impairment, delirium and the various dementia syndromes. It is an independent predictor of excess mortality1 and increases the risk of adverse medication effects from benzodiazepines and anticholinergics.


  • George Washington University, Washington, DC, USA


Correspondence: ecobbs@mfa.gwu.edu

Series editors

Balakrishnan (Kichu) Nair

Simon O’Connor


Competing interests:

No relevant disclosures.

  • 1. Sachs GA, Carter R, Holtz LR, et al. Cognitive impairment: an independent predictor of excess mortality: a cohort study. Ann Intern Med 2011; 155: 300-308.
  • 2. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia — meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009; 119: 252-265.
  • 3. Lin JS, O’Connor E, Rossom RC, et al. Screening for cognitive impairment in older adults: a systematic review for the US Preventive Services Task Force. Ann Intern Med 2013; 159: 601-612.
  • 4. Borson S, Scanlan JM, Watanabe J, et al. Improving identification of cognitive impairment in primary care. Int J Geriatr Psychiatry 2006; 21: 349-355.
  • 5. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
  • 6. Wong CL, Holroyd-Leduc, Simel DL, Straus SE. Does this patient have delirium?: value of bedside instruments. JAMA 2010; 304: 779-786.
  • 7. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695-699.
  • 8. Tariq SH, Tumosa N, Chibnall JT, et al. Comparison of the Saint Louis University Mental Status Examination and the Mini-Mental State Examination for detecting dementia and mild neurocognitive disorder: a pilot study. Am J Geriatr Psychiatry 2006; 14: 900-910.
  • 9. Jorm AF. A short form of the informant questionnaire on cognitive decline in the elderly (IQCODE): development and cross-validation. Psychol Med 1994; 24: 145-153.
Online responses are no longer available. Please refer to our instructions for authors page for more information.

Will Australia have a fit-for-purpose medical workforce in 2025?

Roger P Strasser
Med J Aust 2018; 208 (5): . || doi: 10.5694/mja17.01169
Published online: 19 March 2018

To produce a fit-for-purpose medical workforce, Australia needs streamlined training pathways in all medical disciplines

Around the world, there has been a developing focus over the past decade on the importance of a fit-for-purpose medical workforce1 with the right skills, providing the right care, in the right place, at the right time, and with skill sets which include leadership skills, communication expertise and the ability to work within teams.2 Coupled with this is the perspective that health care should address the needs of patients and the public as its central purpose.3 The underlying assumption is that the provision of medical and other health care should be designed and delivered to meet the health needs of the population being served.


  • Northern Ontario School of Medicine, Laurentian and Lakehead Universities, Sudbury, ON, Canada


Correspondence: Roger.Strasser@nosm.ca

Competing interests:

No relevant disclosures.

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Pagination

Subscribe to